GS1-144 is under clinical development by Changchun Jinsai Pharmaceutical and currently in Phase I for Vasomotor Symptoms (Non-Menopausal). According to GlobalData, Phase I drugs for Vasomotor Symptoms (Non-Menopausal) does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the GS1-144 LoA Report. Buy the report here.
Smarter leaders trust GlobalData
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
GS1-144 overview
GS1-144 is under development for the treatment of vasomotor disease. It is administered through oral route as a tablet. The drug candidate acts by targeting NK-3R.
Changchun Jinsai Pharmaceutical overview
Changchun Jinsai Pharmaceutical, a subsidiary of Changchun High-Tech Industry Group Co Ltd, is a biopharmaceutical company engaged in research, development and production of novel drugs in the field of child and women’s healthcare. The company is headquartered in Changchun, Jilin, China.
For a complete picture of GS1-144’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
